532 related articles for article (PubMed ID: 20516278)
21. Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay.
Ludmerer SW; Graham DJ; Boots E; Murray EM; Simcoe A; Markel EJ; Grobler JA; Flores OA; Olsen DB; Hazuda DJ; LaFemina RL
Antimicrob Agents Chemother; 2005 May; 49(5):2059-69. PubMed ID: 15855532
[TBL] [Abstract][Full Text] [Related]
22. INX-08189, a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties.
Vernachio JH; Bleiman B; Bryant KD; Chamberlain S; Hunley D; Hutchins J; Ames B; Gorovits E; Ganguly B; Hall A; Kolykhalov A; Liu Y; Muhammad J; Raja N; Walters CR; Wang J; Williams K; Patti JM; Henson G; Madela K; Aljarah M; Gilles A; McGuigan C
Antimicrob Agents Chemother; 2011 May; 55(5):1843-51. PubMed ID: 21357300
[TBL] [Abstract][Full Text] [Related]
23. Discovery of a 2'-fluoro-2'-C-methyl C-nucleotide HCV polymerase inhibitor and a phosphoramidate prodrug with favorable properties.
Kirschberg TA; Metobo S; Clarke MO; Aktoudianakis V; Babusis D; Barauskas O; Birkus G; Butler T; Byun D; Chin G; Doerffler E; Edwards TE; Fenaux M; Lee R; Lew W; Mish MR; Murakami E; Park Y; Squires NH; Tirunagari N; Wang T; Whitcomb M; Xu J; Yang H; Ye H; Zhang L; Appleby TC; Feng JY; Ray AS; Cho A; Kim CU
Bioorg Med Chem Lett; 2017 Apr; 27(8):1840-1847. PubMed ID: 28274633
[TBL] [Abstract][Full Text] [Related]
24. Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052.
Wang C; Huang H; Valera L; Sun JH; O'Boyle DR; Nower PT; Jia L; Qiu D; Huang X; Altaf A; Gao M; Fridell RA
Antimicrob Agents Chemother; 2012 Mar; 56(3):1350-8. PubMed ID: 22214777
[TBL] [Abstract][Full Text] [Related]
25. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977.
Murakami E; Tolstykh T; Bao H; Niu C; Steuer HM; Bao D; Chang W; Espiritu C; Bansal S; Lam AM; Otto MJ; Sofia MJ; Furman PA
J Biol Chem; 2010 Nov; 285(45):34337-47. PubMed ID: 20801890
[TBL] [Abstract][Full Text] [Related]
26. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
Yu M; Corsa AC; Xu S; Peng B; Gong R; Lee YJ; Chan K; Mo H; Delaney W; Cheng G
Antiviral Res; 2013 Nov; 100(2):439-45. PubMed ID: 24013001
[TBL] [Abstract][Full Text] [Related]
27. Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.
Shi ST; Herlihy KJ; Graham JP; Nonomiya J; Rahavendran SV; Skor H; Irvine R; Binford S; Tatlock J; Li H; Gonzalez J; Linton A; Patick AK; Lewis C
Antimicrob Agents Chemother; 2009 Jun; 53(6):2544-52. PubMed ID: 19307358
[TBL] [Abstract][Full Text] [Related]
28. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796.
Howe AY; Cheng H; Johann S; Mullen S; Chunduru SK; Young DC; Bard J; Chopra R; Krishnamurthy G; Mansour T; O'Connell J
Antimicrob Agents Chemother; 2008 Sep; 52(9):3327-38. PubMed ID: 18559648
[TBL] [Abstract][Full Text] [Related]
29. Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
Sofia MJ; Bao D; Chang W; Du J; Nagarathnam D; Rachakonda S; Reddy PG; Ross BS; Wang P; Zhang HR; Bansal S; Espiritu C; Keilman M; Lam AM; Steuer HM; Niu C; Otto MJ; Furman PA
J Med Chem; 2010 Oct; 53(19):7202-18. PubMed ID: 20845908
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and characterization of 1'-C-cyano-2'-fluoro-2'-C-methyl pyrimidine nucleosides as HCV polymerase inhibitors.
Kirschberg TA; Mish MR; Zhang L; Squires NH; Wang KY; Cho A; Feng JY; Fenaux M; Babusis D; Park Y; Ray AS; Kim CU
Bioorg Med Chem Lett; 2015 Mar; 25(5):1040-3. PubMed ID: 25650256
[TBL] [Abstract][Full Text] [Related]
31. Nucleoside analog inhibitors of hepatitis C virus replication.
Carroll SS; Olsen DB
Infect Disord Drug Targets; 2006 Mar; 6(1):17-29. PubMed ID: 16787301
[TBL] [Abstract][Full Text] [Related]
32. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase.
Ahmed-Belkacem A; Ahnou N; Barbotte L; Wychowski C; Pallier C; Brillet R; Pohl RT; Pawlotsky JM
Gastroenterology; 2010 Mar; 138(3):1112-22. PubMed ID: 19962982
[TBL] [Abstract][Full Text] [Related]
33. Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.
Herlihy KJ; Graham JP; Kumpf R; Patick AK; Duggal R; Shi ST
Antimicrob Agents Chemother; 2008 Oct; 52(10):3523-31. PubMed ID: 18694956
[TBL] [Abstract][Full Text] [Related]
34. Chemical genetics-based discovery of indole derivatives as HCV NS5B polymerase inhibitors.
Jin G; Lee S; Choi M; Son S; Kim GW; Oh JW; Lee C; Lee K
Eur J Med Chem; 2014 Mar; 75():413-25. PubMed ID: 24561671
[TBL] [Abstract][Full Text] [Related]
35. Comparison of HCV NS3 protease and NS5B polymerase inhibitor activity in 1a, 1b and 2a replicons and 2a infectious virus.
Paulson MS; Yang H; Shih IH; Feng JY; Mabery EM; Robinson MF; Zhong W; Delaney WE
Antiviral Res; 2009 Aug; 83(2):135-42. PubMed ID: 19457562
[TBL] [Abstract][Full Text] [Related]
36. A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors.
Chase R; Skelton A; Xia E; Curry S; Liu S; McMonagle P; Huang HC; Tong X
Antiviral Res; 2009 Nov; 84(2):178-84. PubMed ID: 19747948
[TBL] [Abstract][Full Text] [Related]
37. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.
Bilello JP; Lallos LB; McCarville JF; La Colla M; Serra I; Chapron C; Gillum JM; Pierra C; Standring DN; Seifer M
Antimicrob Agents Chemother; 2014 Aug; 58(8):4431-42. PubMed ID: 24867983
[TBL] [Abstract][Full Text] [Related]
38. Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.
Chen CM; He Y; Lu L; Lim HB; Tripathi RL; Middleton T; Hernandez LE; Beno DW; Long MA; Kati WM; Bosse TD; Larson DP; Wagner R; Lanford RE; Kohlbrenner WE; Kempf DJ; Pilot-Matias TJ; Molla A
Antimicrob Agents Chemother; 2007 Dec; 51(12):4290-6. PubMed ID: 17908950
[TBL] [Abstract][Full Text] [Related]
39. Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase.
Shih IH; Vliegen I; Peng B; Yang H; Hebner C; Paeshuyse J; Pürstinger G; Fenaux M; Tian Y; Mabery E; Qi X; Bahador G; Paulson M; Lehman LS; Bondy S; Tse W; Reiser H; Lee WA; Schmitz U; Neyts J; Zhong W
Antimicrob Agents Chemother; 2011 Sep; 55(9):4196-203. PubMed ID: 21746939
[TBL] [Abstract][Full Text] [Related]
40. In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance.
Le Pogam S; Jiang WR; Leveque V; Rajyaguru S; Ma H; Kang H; Jiang S; Singer M; Ali S; Klumpp K; Smith D; Symons J; Cammack N; Nájera I
Virology; 2006 Aug; 351(2):349-59. PubMed ID: 16713611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
